Pharmaceutical combination comprising a COX-2 inhibitor and a iNOS inhibitor
Patent 6248745 Issued on June 19, 2001. Estimated Expiration Date: 
September 1, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
September 1, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorsAssigneeApplicationNo. 380379 filed on 09/01/1999US Classes:514/266.2, Additional hetero ring attached directly or indirectly to the quinazoline ring system by nonionic bonding514/255.05, Additional hetero ring attached directly or indirectly to the 1,4-diazine ring by nonionic bonding514/266.21, The additional hetero ring is six-membered consisting of one nitrogen and five carbons514/266.22, Piperidinyl or tetrahydropyridyl514/406, Pyrazoles514/473Chalcogen bonded directly to the hetero ringExaminersPrimary: Jarvis, William R. A.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/505A61K 031/415 A61K 031/34 Foreign Application Priority Data1998-06-29 SEAbstractThe invention relates to the co-administration of an inhibitor of induced nitric oxide synthase and an inhibitor of cyclooxygenase-2 for the treatment of inflammation and inflammatory disorders.Other References
| |
